Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Exploratory Clinical Study of Camrelizumab Combined With Concurrent Chemoradiotherapy as an Organ-preserving Strategy for Locally Advanced Resectable Esophageal Squamous Cell Carcinoma

NCT07622797 is registered in ClinicalTrials.gov with The First Affiliated Hospital of Henan University of Science and Technology as lead sponsor.

NCT NCT07622797
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07622797 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Exploratory Clinical Study of Camrelizumab Combined With Concurrent Chemoradiotherapy as an Organ-preserving Strategy for Locally Advanced Resectable Esophageal Squamous Cell Carcinoma
Lead sponsor
The First Affiliated Hospital of Henan University of Science and Technology
Phase
Phase 2
Overall status
Recruiting
Start date
November 21, 2025
Completion date
December 31, 2030
Enrollment
164 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

late-stage resectable esophageal squamous carcinoma